Avadel Pharmaceuticals PLC
NASDAQ:AVDL

Watchlist Manager
Avadel Pharmaceuticals PLC Logo
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Watchlist
Price: 10.23 USD 0.89% Market Closed
Market Cap: 985.8m USD
Have any thoughts about
Avadel Pharmaceuticals PLC?
Write Note

Avadel Pharmaceuticals PLC
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Avadel Pharmaceuticals PLC
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Cash from Operating Activities
-$82.8m
CAGR 3-Years
-4%
CAGR 5-Years
-9%
CAGR 10-Years
-22%
Perrigo Company PLC
NYSE:PRGO
Cash from Operating Activities
$259m
CAGR 3-Years
-11%
CAGR 5-Years
-12%
CAGR 10-Years
-11%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Cash from Operating Activities
$1.2B
CAGR 3-Years
14%
CAGR 5-Years
5%
CAGR 10-Years
13%
Cosmo Pharmaceuticals NV
SIX:COPN
Cash from Operating Activities
€117.3m
CAGR 3-Years
82%
CAGR 5-Years
N/A
CAGR 10-Years
19%
Ovoca Bio PLC
LSE:OVB
Cash from Operating Activities
€404k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Avadel Pharmaceuticals PLC
Glance View

Market Cap
985.5m USD
Industry
Pharmaceuticals
Economic Moat
None

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

AVDL Intrinsic Value
18.02 USD
Undervaluation 43%
Intrinsic Value
Price

See Also

What is Avadel Pharmaceuticals PLC's Cash from Operating Activities?
Cash from Operating Activities
-82.8m USD

Based on the financial report for Sep 30, 2024, Avadel Pharmaceuticals PLC's Cash from Operating Activities amounts to -82.8m USD.

What is Avadel Pharmaceuticals PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-22%

Over the last year, the Cash from Operating Activities growth was 29%. The average annual Cash from Operating Activities growth rates for Avadel Pharmaceuticals PLC have been -4% over the past three years , -9% over the past five years , and -22% over the past ten years .

Back to Top